Navigation Links
CerSci Therapeutics Awarded $225K Phase I NIH SBIR Grant for the Treatment of Neuropathic Pain
Date:3/8/2017

DALLAS, March 8, 2017 /PRNewswire/ -- CerSci Therapeutics, a pharmaceutical development company based in Dallas, Texas, today announced it has been awarded a Phase I SBIR grant of $225,000 from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) to continue its development of novel non-opioid drug candidates for the treatment of chronic neuropathic pain. 

CerSci Therapeutics, founded in early 2015, is focused on developing next-generation non-opioid pain therapeutics for the treatment and prevention of acute and chronic pain. This grant will enable CerSci to further develop their patented and patent-pending pipeline of adenosine monophosphate activated protein kinase (AMPK) activators and peroxynitrite (PN) scavengers.  CerSci's development of non-opioid pain therapeutics addresses the critical need of finding solutions to the opioid epidemic in the U.S.  According to the U.S. Center for Disease Control, the United States is in the midst of an opioid overdose epidemic; opioids killed more than 33,000 Americans (90 people per day) in 2015, with half of all opioid overdose deaths involving a prescription opioid.

"Healthcare expenditures associated with chronic pain account for over $600 billion annually, more than the yearly cost of cancer, and heart disease combined. However, treatments available for these patients are very limited," remarked Dr. Lucas Rodriguez, Co-Founder and President of CerSci Therapeutics. "Alarmingly, 1 in 4 patients who treat chronic pain with opioids struggle with addiction. At CerSci, we believe that developing drugs, which avoid interaction with opioid receptors altogether, will aid in the relief of the opioid epidemic while providing caregivers drugs, which will truly help alleviate their patients' pain. We are incredibly energized to receive this validation from our peers at the NIH."

CerSci Therapeutics is currently fundraising to support the Investigational New Drug Application for their lead molecular asset to the Food and Drug Administration.

Media Contact:
Lucas Rodriguez
+1 (956) 279-6888
www.cersci.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cersci-therapeutics-awarded-225k-phase-i-nih-sbir-grant-for-the-treatment-of-neuropathic-pain-300419617.html


'/>"/>
SOURCE CerSci Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Dermatology Diagnostic Devices and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
2. Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
3. Bellerophon Therapeutics and Worldwide Clinical Trials Selected as Finalists in 2017 Care Awards
4. ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017
5. Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
6. Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
7. How These Biotech Stocks are Faring? -- Geron, Incyte, Illumina, and Bellerophon Therapeutics
8. Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting
9. Global Breast Cancer Therapeutics Market Analysis 2016-2022: Company Profiling Covering the Financials, Recent Activities and Future Strategies - Research and Markets
10. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Strategic Business Report 2017-2022 - Research and Markets
11. United Therapeutics Corporation To Present At Cowen And Company 37th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):